DUTASTERIDE 0.1% + MINOXIDIL 5%

DUTASTERIDE 0.1% + MINOXIDIL 5%

€0,00
Skip to product information
DUTASTERIDE 0.1% + MINOXIDIL 5%
Research Formulation • Topical Delivery System

DUTASTERIDE 0.1% / MINOXIDIL 5%

Topical Research Solution
CAS No. Dutasteride: 164656-23-9 / Minoxidil: 38304-91-5
Format 0.1% w/v Dutasteride + 5% w/v Minoxidil
Volume 50 mL
Access request-only

Dual-compound, solvent-based topical research formulation developed for localized, non-clinical 5α-reductase pathway and androgen receptor interaction studies.

Submit Formulation Request

Prefer email communication?
Request this formulation via our consultation form.

Request-only supply. No instant checkout. All formulation requests are reviewed before fulfilment.

Technical Data
Chemical Identification
Chemical Name Dutasteride / Minoxidil dual-compound topical research formulation
Synonyms Dutasteride Minoxidil MX-DU dual-compound topical research formulation
Molecular Formula Dutasteride: C27H30F6N2O2 / Minoxidil: C9H15N5O
Molecular Weight Dutasteride: 528.53 g/mol / Minoxidil: 209.25 g/mol
Compound Class 5α-reductase inhibitor + pyrimidine N-oxide topical research compound
Purity Research-grade purity
InChIKey Dutasteride: JWJOTENAMICLJG-QWBYCMEYSA-N / Minoxidil: FJHBPBZWBEKDQZ-UHFFFAOYSA-N
Physicochemical Characteristics
Appearance Clear to slightly opalescent, colorless to faint yellow solution.
Formulation Type Topical Solution
Delivery System Solvent-based topical formulation
Solubility Context Hydroalcoholic multi-solvent carrier architecture utilized to support stable dual-compound dispersion of 0.1% w/v Dutasteride and 5% w/v Minoxidil.
Water Content Contains purified water as part of the hydroalcoholic carrier system.
Storage Store tightly closed in a cool, dry, dark environment.
Stability Stability may vary depending on exposure to heat, light, oxygen, and prolonged environmental stress.
Documentation & Analytical Data
Analytical Standard Research-grade analytical reference
Research Classification Non-clinical research formulation
Laboratory Status Research-use material
Batch Documentation Internal batch documentation and formulation records maintained for research traceability purposes.
Documentation Availability COA / SDS / Batch Records available upon request depending on batch and formulation configuration.
Traceability Batch-level internal reference architecture maintained for controlled formulation tracking.
Research Documentation
Formulation Specification

Concentration system: 0.1% w/v Dutasteride + 5% w/v Minoxidil

Equivalent concentration: 1 mg/mL Dutasteride + 50 mg/mL Minoxidil

Total active content: 50 mg Dutasteride + 2500 mg Minoxidil per 50 mL

Vehicle system: Ethanol 96% (Ph. Eur.) / Propylene Glycol (Ph. Eur.) / Diethylene Glycol Monoethyl Ether — Transcutol® P (Ph. Eur.) / Dimethyl Isosorbide / Purified Water (Ph. Eur.)

Solvent ratio: 40 / 22.5 / 22.5 / 10 / 5

Formulation architecture: Hydroalcoholic multi-solvent topical carrier system designed to support compound solubility, formulation consistency, and controlled surface application modeling.

Water content: Purified water included as part of the carrier system.

Formulation complexity: Dual-compound system

Research Context

This dual-compound topical formulation combines Dutasteride and Minoxidil for non-clinical research models involving localized androgen pathway interaction, follicular response investigation, carrier-system compatibility, and surface-applied compound behavior.

In topical research contexts, the formulation is evaluated as a solvent-based dual-compound system where localized delivery behavior, compound dispersion, hydroalcoholic carrier compatibility, and formulation consistency are relevant experimental parameters.

Experimental focus is generally directed toward surface-confined delivery architecture, combined compound dispersion behavior, and controlled localized exposure modeling within non-clinical laboratory environments.

This GeneTherica formulation is positioned as a research-grade topical solution for controlled, non-clinical laboratory use. It is not supplied for therapeutic, diagnostic, cosmetic, or human application.

Storage & Handling

Storage range: 15–25°C under controlled room-temperature conditions.

Storage conditions: Store tightly closed in a cool, dry, dark environment.

Light sensitivity: Protect from direct sunlight and UV exposure.

Temperature stability: Avoid freezing and excessive heat exposure.

Air exposure: Minimize prolonged exposure to air.

Closure requirement: Keep container tightly sealed when not in use.

Stability context: Storage conditions are intended to support solvent balance, formulation consistency, and compound stability during controlled non-clinical handling.

Research Use Notice

Supplied exclusively for laboratory research and analytical applications.

Not intended for therapeutic, cosmetic, veterinary, food, household, diagnostic, or human application.

Handling should occur within qualified non-clinical research environments only.

Vehicle System
Multi-Solvent Carrier Architecture
Ethanol 96% Ph. Eur.
Propylene Glycol Ph. Eur.
Transcutol® P Ph. Eur.
Dimethyl Isosorbide Ph. Eur.
Purified Water Ph. Eur.
Solvent Ratio 40 / 22.5 / 22.5 / 10 / 5
Research Use Notice
GeneTherica products are supplied for research use only. Products are not medicines, cosmetics, or approved therapeutic agents.
Documentation Availability
COA / SDS / Batch Records
Available upon request depending on batch and formulation configuration.
Research-Grade Quality
Manufactured under defined quality standards for consistent research performance.
Topical Delivery System
Solvent-based formulation designed for localized and targeted research applications.
Transparency
Full documentation and traceability for every research batch.
Secure & Confidential
Your research and inquiries are handled with complete confidentiality.

Overview

Dutasteride + Minoxidil is a dual-compound topical research formulation investigated within controlled non-clinical environments involving localized 5α-reductase pathway interaction, topical carrier behavior, and compound dispersion modeling.

Within topical research frameworks, Dutasteride is commonly examined for its interaction with localized 5α-reductase-related signaling pathways, while Minoxidil is investigated in experimental models involving topical formulation behavior, localized exposure systems, and surface-confined compound distribution.

Experimental focus is generally directed toward localized biochemical interaction behavior, compound compatibility within hydroalcoholic multi-solvent carrier systems, and controlled delivery architecture associated with topical research formulations.

Research applications emphasize surface-confined topical carrier systems designed to support formulation consistency, compound dispersion behavior, solvent balance, and localized exposure modeling within controlled laboratory environments.

This formulation is presented as a research-grade topical solution intended exclusively for scientific, analytical, and laboratory-based investigation under appropriately controlled non-clinical handling conditions.

Laboratory liquid surface
Scientific liquid wave
Laboratory glassware
GeneTherica Documentation Infrastructure

Research Documentation & Technical Systems

Documentation architecture associated with the RU58841 topical research system, including batch-level analytical reference, solvent-system infrastructure, physicochemical handling orientation, and controlled safety documentation access.
Research Infrastructure
Technical Documentation Layer
GeneTherica documentation systems are structured around controlled formulation architecture, analytical reference context, solvent-system engineering, and batch-oriented research documentation.
Research Overview →
Physicochemical Orientation
Documentation emphasizes solvent compatibility, evaporation behavior, crystallization prevention, and controlled carrier architecture.
Batch-Level Structure
Technical references may include batch identifiers, analytical specification context, and raw material traceability layers.
Research Context
Documentation infrastructure is intended for controlled non-clinical research orientation and laboratory identification purposes.
Controlled Systems
Access to certain documentation layers may depend on compound configuration, formulation type, and request evaluation.